

PATENT COOPERATION T<sup>RY</sup> ATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year)  
13 June 2000 (13.06.00)

International application No.  
PCT/US99/23764

Applicant's or agent's file reference  
DEX-0048

International filing date (day/month/year)  
18 October 1999 (18.10.99)

Priority date (day/month/year)  
19 October 1998 (19.10.98)

## Applicant

ALI, Shujath, M. et al

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

09 May 2000 (09.05.00)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Pascal Piriou

Telephone No.: (41-22) 338.83.38

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

**PCT**

**AUG 21 2000**

To: JANE MASSEY LICATA  
LAW OFFICES OF JANE MASSEY LICATA  
66 E. MAIN STREET  
MARLTON, NEW JERSEY 08053 US

Docket System ☒  
Status Report ☒  
Docket Book ☒

10/16/00 ANS

**WRITTEN OPINION**

(PCT Rule 66)

Date of Mailing  
(day/month/year)

**16 AUG 2000**

Applicant's or agent's file reference

DEX-0048

**REPLY DUE**

within TWO months  
from the above date of mailing

International application No.

PCT/US99/23764

International filing date (day/month/year)

18 OCTOBER 1999

Priority date (day/month/year)

19 OCTOBER 1998

International Patent Classification (IPC) or both national classification and IPC  
Please See Supplemental Sheet.

Applicant

DIADEXUS LLC

1. This written opinion is the first (first, etc.) drawn by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

3. The applicant is hereby invited to reply to this opinion.

When? See the time limit indicated above. ~~The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).~~

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also For an additional opportunity to submit amendments, see Rule 66.4.  
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.  
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 19 FEBRUARY 2001

Name and mailing address of the IPEA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

*Geetha P. Bansal*  
GEETHA P. BANSAL

Telephone No. (703) 308-0196

**I. Basis of the opinion****1. With regard to the elements of the international application:\***

- ☒ the international application as originally filed
- ☒ the description:  
pages 1-24, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the claims:  
pages 25-27, as originally filed  
pages NONE, as amended (together with any statement) under Article 19  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the drawings:  
pages NONE, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the sequence listing part of the description:  
pages NONE, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_

**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written opinion was drawn on the basis of the sequence listing:**

- ☐ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

**4. ☒ The amendments have resulted in the cancellation of:**

- ☒ the description, pages NONE
- ☒ the claims, Nos. NONE
- ☒ the drawings, sheets/fig NONE

**5. ☐ This opinion has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".

**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. statement**

Novelty (N)	Claims <u>7-11</u>	YES
	Claims <u>1-6</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-11</u>	NO
Industrial Applicability (IA)	Claims <u>1-11</u>	YES
	Claims <u>NONE</u>	NO

**2. citations and explanations**

Claims 1-6 lack novelty under PCT Article 33(2) as being anticipated by Olsson et al (1997) and Cho-Chung et al (1993).

The claims are drawn to methods of diagnosing, staging and monitoring the metastatic potential of prostate cancer by identifying or detecting an increase in CSGs or cancer specific genes, in a patient. The claims are also drawn to a method of identifying therapeutic agents that bind to CSGs. Olsson et al teach the diagnosis, staging, monitoring metastasis of prostate cancer. Olsson et al teach that tumor cells exhibit abnormally rearranged or mutated genes that are not present in normal cells (these can be considered cancer specific genes). Olsson et al teach RT-PCR as well as quantitative RT-PCR technology as applicable to the above mentioned methods, and applying the technology to various tissue and body fluid samples.

Cho-Chung et al teach the use of nucleic acid in the therapy of neoplasia with specific reference to anti-sense oligonucleotides. The disclosure of Cho-Chung et al inherently teaches a method of identifying potential candidates that will bind to the CSGs in prostate cancer.

Claims 7-11 lack an inventive step under PCT Article 33(3) as being obvious over Olsson et al (1997) and Cho-Chung et al (1993). The claims are drawn to methods of diagnosing, staging and monitoring the metastatic potential of prostate cancer by identifying or detecting an increase in CSGs or cancer specific genes, in a patient wherein the CSGs comprise the SEQ IDs recited in the claims. The claims are also drawn to a method of identifying therapeutic agents that bind to the said CSGs. Olsson et al teach the diagnosis, staging, monitoring metastasis of prostate cancer. Olsson et al teach that tumor cells exhibit abnormally rearranged or mutated genes that are not present in normal cells (these can be considered cancer specific genes). Olsson et al teach RT-PCR as well as quantitative RT-PCR technology as applicable to the above mentioned methods, and applying the technology to various tissue and body fluid samples.

Cho-Chung et al teach the use of nucleic acid in the therapy of neoplasia with specific reference to anti-sense oligonucleotides. (Continued on Supplemental Sheet.)

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**TIME LIMIT:**

The time limit set for response to a Written Opinion may not be extended. 37 CFR 1.484(d). Any response received after the expiration of the time limit set in the Written Opinion will not be considered in preparing the International Preliminary Examination Report.

**CLASSIFICATION:**

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(7): A61K 39/395, 48/00; C12P/ 19/34; C12Q 1/68; G01N 33/53, 33/574, 33/546, 33/567 and US Cl.: 424/130.1, 141.1, 155.1, 183.1; 435/6, 7.1, 7.23, 7.9, 91.2; 436/501, 504, 505, 547; 514/44; 536/ 23.5

**V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):**

The disclosure of Cho-Chung et al inherently teaches a method of identifying potential candidates that will bind to the CSGs in prostate cancer. Though the above cited art do not specifically mention the SEQ ID Nos, it would have been obvious to one of ordinary skill in the art at the time of the invention to extend the methods wherein the PSA or PMSA have been replaced with the SEQ ID NOs recited in the claims. One of ordinary skill in the art would have been motivated to do so because the prior art teaches that cancer specific genes include any genes that are expressed by cancer cells and not by normal cells. Absent any unexpected results by the inclusion of the SEQ ID Nos recited in the claims, the use of these sequences in a method of diagnosing, staging and monitoring the metastatic potential of prostate cancer would have been obvious to do for one of ordinary skill in the art. Furthermore, it would have been obvious to one of ordinary skill in the art to have produced antibodies to the CSGs as the art of making antibodies to peptides, proteins or other biochemical, molecules are routine in the art. The use of antibodies to the CSGs as an immunotoxin or in methods of detection would also have been obvious.

----- NEW CITATIONS -----  
NONE

09/807200

JC08 Rec'd PCT/PTO 10 APR 2001

**FOR THE PURPOSES OF INFORMATION ONLY**


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference DEX-0048	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/23764	International filing date (day/month/year) 18 OCTOBER 1999	Priority date (day/month/year) 19 OCTOBER 1998
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant DIADEXUS LLC		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 4 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  09 MAY 2000	Date of completion of this report  19 JANUARY 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer  GEETHA P. BANSAL
Facsimile No. (703) 305-3230	Telephone No. (703) 305-3955

**I. Basis of the report****1. With regard to the elements of the international application:\***☒ the international application as originally filed☒ the description:

pages 1-24 , as originally filed  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

☒ the claims:

pages 25-27 , as originally filed  
pages NONE , as amended (together with any statement) under Article 19  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

☒ the drawings:

pages NONE , as originally filed  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

☒ the sequence listing part of the description:

pages NONE , as originally filed  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).  
☐ the language of publication of the international application (under Rule 48.3(b)).  
☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**

- ☐ contained in the international application in printed form.  
☐ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority in written form.  
☐ furnished subsequently to this Authority in computer readable form.  
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

**4. ☒ The amendments have resulted in the cancellation of:**

- ☒ the description, pages NONE  
☒ the claims, Nos. NONE  
☒ the drawings, sheets/fig NONE

**5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\*Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.



**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. statement**

Novelty (N)

Claims 7-11 YESClaims 1-6 NO

Inventive Step (IS)

Claims NONE YESClaims 1-11 NO

Industrial Applicability (IA)

Claims 1-11 YESClaims NONE NO**2. citations and explanations (Rule 70.7)**

Claims 1-6 lack novelty under PCT Article 33(2) as being anticipated by Olsson et al (1997) and Cho-Chung et al (1993).

The claims are drawn to methods of diagnosing, staging and monitoring the metastatic potential of prostate cancer by identifying or detecting an increase in CSGs or cancer specific genes, in a patient. The claims are also drawn to a method of identifying therapeutic agents that bind to CSGs. Olsson et al teach the diagnosis, staging, monitoring metastasis of prostate cancer. Olsson et al teach that tumor cells exhibit abnormally rearranged or mutated genes that are not present in normal cells (these can be considered cancer specific genes). Olsson et al teach RT-PCR as well as quantitative RT-PCR technology as applicable to the above mentioned methods, and applying the technology to various tissue and body fluid samples. Cho-Chung et al teach the use of nucleic acid in the therapy of neoplasia with specific reference to anti-sense oligonucleotides. The disclosure of Cho-Chung et al inherently teaches a method of identifying potential candidates that will bind to the CSGs in prostate cancer.

Claims 7-11 lack an inventive step under PCT Article 33(3) as being obvious over Olsson et al (1997) and Cho-Chung et al (1993). The claims are drawn to methods of diagnosing, staging and monitoring the metastatic potential of prostate cancer by identifying or detecting an increase in CSGs or cancer specific genes, in a patient wherein the CSGs comprise the SEQ IDs recited in the claims. The claims are also drawn to a method of identifying therapeutic agents that bind to the said CSGs. Olsson et al teach the diagnosis, staging, monitoring metastasis of prostate cancer. Olsson et al teach that tumor cells exhibit abnormally rearranged or mutated genes that are not present in normal cells (these can be considered cancer specific genes). Olsson et al teach RT-PCR as well as quantitative RT-PCR technology as applicable to the above mentioned methods, and applying the technology to various tissue and body fluid samples. Cho-Chung et al teach the use of nucleic acid in the therapy of neoplasia with specific reference to anti-sense oligonucleotides. (Continued on Supplemental Sheet.)

**Supplemental B x**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**CLASSIFICATION:**

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(7): A61K 39/395, 48/00; C12P/ 19/34; C12Q 1/68; G01N 33/53, 33/574, 33/546, 33/567 and US Cl.: 424/130.1, 141.1, 155.1, 183.1; 435/6, 7.1, 7.23, 7.9, 91.2; 436/501, 504, 505, 547; 514/44; 536/ 23.5

**V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):**

The disclosure of Cho-Chung et al inherently teaches a method of identifying potential candidates that will bind to the CSGs in prostate cancer. Though the above cited art do not specifically mention the SEQ ID Nos, it would have been obvious to one of ordinary skill in the art at the time of the invention to extend the methods wherein the PSA or PMSA have been replaced with the SEQ ID NOs recited in the claims. One of ordinary skill in the art would have been motivated to do so because the prior art teaches that cancer specific genes include any genes that are expressed by cancer cells and not by normal cells. Absent any unexpected results by the inclusion of the SEQ ID Nos recited in the claims, the use of these sequences in a method of diagnosing, staging and monitoring the metastatic potential of prostate cancer would have been obvious to do for one of ordinary skill in the art. Furthermore, it would have been obvious to one of ordinary skill in the art to have produced antibodies to the CSGs as the art of making antibodies to peptides, proteins or other biochemical molecules are routine in the art. The use of antibodies to the CSGs as an immunotoxin or in methods of detection would also have been obvious.

----- NEW CITATIONS -----  
NONE



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 39/395, 48/00, C12P 19/34, C12Q 1/68, G01N 33/53, 33/574, 33/546, 33/567</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/23108</b> <b>(43) International Publication Date:</b> 27 April 2000 (27.04.00)
<b>(21) International Application Number:</b> PCT/US99/23764 <b>(22) International Filing Date:</b> 18 October 1999 (18.10.99)  <b>(30) Priority Data:</b> 60/104,741 19 October 1998 (19.10.98) US  <b>(71) Applicant (for all designated States except US):</b> DIADEXUS LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> ALI, Shujath, M. [IN/US]; 3475 Granada Avenue, #357, Santa Clara, CA 95051 (US). SUN, Yongming [CN/US]; Apartment 260, 869 S. Winchester Boulevard, San Jose, CA 95128 (US). SALCEDA, Susana [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). RECIPON, Herve [FR/US]; 85 Fortuna Avenue, San Francisco, CA 94115 (US). CAFFERKEY, Robert [IE/US]; Apartment #218, 350 Elan Village Lane, San Jose, CA 95134 (US).  <b>(74) Agents:</b> LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).		<b>(81) Designated States:</b> CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING PROSTATE CANCER		
<b>(57) Abstract</b>  The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**METHOD OF DIAGNOSING,  
MONITORING, STAGING, IMAGING AND TREATING PROSTATE CANCER**

**FIELD OF THE INVENTION**

This invention relates, in part, to newly developed  
5 assays for detecting, diagnosing, monitoring, staging,  
prognosticating, imaging and treating cancers, particularly  
prostate cancer.

**BACKGROUND OF THE INVENTION**

Cancer of the prostate is the most prevalent malignancy  
10 in adult males, excluding skin cancer, and is an increasingly  
prevalent health problem in the United States. In 1996, it  
was estimated that 41,400 deaths would result from this  
disease in the United States alone, indicating that prostate  
cancer is second only to lung cancer as the most common cause  
15 of death in the same population. If diagnosed and treated  
early, when the cancer is still confined to the prostate, the  
chances of cure is significantly higher.

Treatment decisions for an individual are linked to the  
stage of prostate cancer present in that individual. A common  
20 classification of the spread of prostate cancer was developed  
by the American Urological Association (AUA). The AUA system  
divides prostate tumors into four stages, A to D. Stage A,  
microscopic cancer within prostate, is further subdivided into  
sub-stages A1 and A2. Sub-stage A1 is a well-differentiated  
25 cancer confined to one site within the prostate. Treatment  
is generally observation, radical prostatectomy, or radiation.  
Sub-stage A2 is a moderately to poorly differentiated cancer  
at multiple sites within the prostate. Treatment is radical  
prostatectomy or radiation. Stage B, palpable lump within the

- 2 -

prostate, is also further subdivided into sub-stages B1 and B2. In sub-stage B1, the cancer forms a small nodule in one lobe of the prostate. In sub-stage B2, the cancer forms large or multiple nodules, or occurs in both lobes of the prostate.

5 Treatment for sub-stages B1 and B2 is either radical prostatectomy or radiation. Stage C is a large cancer mass involving most or all of the prostate and is also further subdivided into two stages. In sub-stage C1, the cancer forms a continuous mass that may have extended beyond the prostate.

10 In sub-stage C2, the cancer forms a continuous mass that invades the surrounding tissue. Treatment for both these sub-stages is radiation with or without drugs to address the cancer. The fourth stage, Stage D is metastatic cancer and is also subdivided into two sub-stages. In sub-stage D1, the

15 cancer appears in the lymph nodes of the pelvis. In sub-stage D2, the cancer involves tissues beyond lymph nodes. Treatment for both of these sub-stages is systemic drugs to address the cancer as well as pain.

However, current prostate cancer staging methods are

20 limited. As many as 50% of prostate cancers initially staged as A2, B, or C are actually stage D, metastatic. Discovery of metastasis is significant because patients with metastatic cancers have a poorer prognosis and require significantly different therapy than those with localized cancers. The five

25 year survival rates for patients with localized and metastatic prostate cancers are 93% and 29%, respectively.

Accordingly, there is a great need for increasingly sensitive methods for diagnosing and staging of prostate cancer in a human patient to determine whether or not such

30 cancer has metastasized and for monitoring the progress of a cancer which has not metastasized for the onset of metastasis.

- 3 -

In the present invention, methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer via the cancer specific gene referred to herein as CSG. CSG refers, among other things, to native protein expressed by the gene comprising the polynucleotide sequence of SEQ ID NO:1. The amino acid sequence of a polypeptide encoded by SEQ ID NO:1 is depicted herein as SEQ ID NO:2. In the alternative, what is meant by CSG as used herein, means the native mRNA encoded by the gene comprising the polynucleotide sequence of SEQ ID NO:1 or levels of the gene comprising the polynucleotide sequence of SEQ ID NO:1.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of prostate cancer by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein a change in levels of

- 4 -

CSG in the patient versus the normal human control is associated with prostate cancer.

Further provided is a method of diagnosing metastatic prostate cancer in a patient having prostate cancer which is not known to have metastasized by identifying a human patient suspected of having prostate cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in CSG levels in the patient versus the normal human control is associated with prostate cancer which has metastasized.

Also provided by the invention is a method of staging prostate cancer in a human which has such cancer by identifying a human patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

Further provided is a method of monitoring prostate cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in



- 5 -

preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

5 Further provided is a method of monitoring the change in stage of prostate cancer in a human having such cancer by looking at levels of CSG in a human having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing a sample of cells, tissues, or  
10 bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is  
15 associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

Further provided are antibodies targeted against CSG or fragments of such antibodies which can be used to detect or  
20 image localization of CSG in a patient for the purpose of detecting or diagnosing a disease or condition. Such antibodies can be polyclonal, monoclonal, or omniconal or prepared by molecular biology techniques. The term "antibody", as used herein and throughout the instant  
25 specification is also meant to include aptamers and single-stranded oligonucleotides such as those derived from an in vitro evolution protocol referred to as SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, but not limited to,  
30 radioisotopes and paramagnetic metals. These antibodies or fragments thereof can also be used as therapeutic agents in

- 6 -

the treatment of diseases characterized by expression of CSG. In therapeutic applications, the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug or a prodrug.

5 Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of  
10 the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

## 15 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging and prognosticating cancers by comparing levels of CSG in a human patient with those of  
20 CSG in a normal human control. What is meant by levels of CSG as used herein, means levels of the native protein expressed by the gene comprising the polynucleotide sequence of SEQ ID NO:1. The amino acid sequence of a polypeptide encoded by SEQ ID NO:1 is depicted herein as SEQ ID NO:2. The native protein  
25 being detected, may be whole, a breakdown product, a complex of molecules or chemically modified. In the alternative, what is meant by levels of CSG as used herein, means levels of the native mRNA encoded by the gene comprising the polynucleotide sequence of SEQ ID NO:1 or levels of DNA comprising the  
30 polynucleotide sequence of SEQ ID NO:1. Such levels are

- 7 -

preferably measured in at least one of cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over-expression of CSG  
5 protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of prostate cancer.

All the methods of the present invention may optionally include measuring the levels of other cancer markers as well  
10 as CSG. Other cancer markers, in addition to CSG, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.

#### ***Diagnostic Assays***

The present invention provides methods for diagnosing the  
15 presence of prostate cancer by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of CSG in the patient versus the normal human control  
20 is associated with the presence of prostate cancer.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues or bodily fluid levels of the cancer marker, such as  
25 CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastatic prostate cancer in a patient having  
30 prostate cancer which has not yet metastasized for the onset of metastasis. In the method of the present invention, a

- 8 -

human cancer patient suspected of having prostate cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art.

5 In the present invention, determining the presence of CSG levels in cells, tissues or bodily fluid, is particularly useful for discriminating between prostate cancer which has not metastasized and prostate cancer which has metastasized. Existing techniques have difficulty discriminating between  
10 prostate cancer which has metastasized and prostate cancer which has not metastasized. However, proper treatment selection is often dependent upon such knowledge.

In the present invention, the cancer marker levels measured in such cells, tissues or bodily fluid is CSG.  
15 Measured levels of CSG are compared with levels of CSG in preferably the same cells, tissue or bodily fluid type of a normal human control. That is, if the cancer marker being observed is just CSG in serum, this level is preferably compared with the level of CSG in serum of a normal human  
20 patient. An increase in CSG levels in the patient versus the normal human control is associated with prostate cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating  
25 the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily  
30 fluid of a normal patient.

- 9 -

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for metastasis, normal human control may preferably also include  
5 samples from a human patient that is determined by reliable methods to have prostate cancer which has not metastasized.

**Staging**

The invention also provides a method of staging prostate cancer in a human patient. The method comprises identifying  
10 a human patient having such cancer and analyzing a sample of cells, tissues or bodily fluid from such human patient for CSG. The measured CSG levels in the patient are then compared with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an  
15 increase in CSG levels in the human patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG (but still increased over true normal levels) is associated with a cancer which is regressing or in remission.

**20 Monitoring**

Further provided is a method of monitoring prostate cancer in a human patient having such cancer for the onset of metastasis. The method comprises identifying a human patient having prostate cancer that is not known to have metastasized;  
25 periodically analyzing cells, tissues or bodily fluid from such human patient for CSG; comparing the CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase in CSG levels in the  
30 human patient versus the normal human control is associated

- 10 -

with a cancer which has metastasized. In this method, normal human control samples may also include prior patient samples.

Further provided by this invention is a method of monitoring the change in stage of prostate cancer in a human patient having such cancer. The method comprises identifying a human patient having prostate cancer; periodically analyzing cells, tissues or bodily fluid from such human patient for CSG; comparing the CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of CSG is associated with a cancer which is regressing in stage or in remission. In this method, normal human control samples may also include prior patient samples.

Monitoring patients for onset of metastasis is periodic and preferably done on a quarterly basis. However, monitoring may be performed more or less frequently depending on the cancer, the particular patient, and the stage of the cancer.

#### ***Assay Techniques***

Assay techniques that can be used to determine levels of gene expression (including protein levels), such as CSG of the present invention, in a sample derived from a patient are well known to those of skill in the art. Such assay methods include, without limitation, radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel based approaches such as mass

- 11 -

spectrometry or protein interaction profiling. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein in biological fluids.

An ELISA assay initially comprises preparing an antibody,  
5 if not readily available from a commercial source, specific to CSG, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to CSG. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or  
10 enzymatic reagent. For example, detectable agents such as horseradish peroxidase enzyme and alkaline phosphatase are routinely used in these types of assays.

To carry out the ELISA, antibody specific to CSG is incubated on a solid support, e.g. a polystyrene dish, that  
15 binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time CSG binds to the specific antibody attached to the polystyrene  
20 dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to CSG and linked to a detectable reagent such as horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to CSG. Unattached reporter  
25 antibody is then washed out. Reagents for detection of peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase linked to CSG antibodies produces a colored reaction product. The amount of color developed in a given time period is proportional to  
30 the amount of CSG protein present in the sample. Quantitative

- 12 -

results typically are obtained by reference to a standard curve.

A competition assay can also be employed wherein antibodies specific to CSG are attached to a solid support. 5 Labeled CSG and a sample derived from the host are then passed over the solid support. The amount of label detected which is attached to the solid support can be correlated to a quantity of CSG in the sample.

Nucleic acid methods can be used to detect CSG mRNA as 10 a marker for prostate cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse- 15 transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse 20 transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of 25 cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e. gridding) can be used to detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the CSG gene is fixed 30 to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or



- 13 -

plastic. At least a portion of the DNA encoding the CSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA isolated from the tissue of interest.

5 Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including, but not limited to, radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene  
10 expression can be done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

15 Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels.  
20 First, proteins are separated by size using an electric current. The current acts uniformly on all proteins so that smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on  
25 the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes or  
30 subsequent protein microsequencing can reveal the relative

- 14 -

abundance of a given protein and the identity of the proteins in the sample.

The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts including both homogenates or solubilized tissue obtained from a human patient. Tissue extracts can be obtained from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. By blood it is meant to include whole blood, plasma, serum or any derivative of blood.

#### *In Vivo Antibody Use*

Antibodies which specifically bind to CSG can also be used *in vivo* in patients suspected of suffering from prostate cancer. Specifically, antibodies which specifically bind a CSG can be injected into a patient suspected of having prostate cancer for diagnostic and/or therapeutic purposes. The preparation and use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use in the radioimmunoscentigraphic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al. J. Clin. Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against CSG can be used in a similar manner. Labeled antibodies which specifically bind CSG can be injected into patients suspected of having prostate

- 15 -

cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or  
5 Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadolinium (III) or Manganese (II) can be used in magnetic resonance imaging  
10 (MRI). Localization of the label permits determination of the spread of the cancer. The amount of label within an organ or tissue also allows determination of the presence or absence of cancer in that organ or tissue.

For patients diagnosed with prostate cancer, injection  
15 of an antibody which specifically binds CSG can also have a therapeutic benefit. The antibody may exert its therapeutic effect alone. Alternatively, the antibody can be conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect. Drug monoclonal antibodies  
20 have been described in the art for example by Garnett and Baldwin, Cancer Research 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. Cell 1986 47:641-648. Yttrium-90 labeled monoclonal antibodies have  
25 been described for maximization of dose delivered to the tumor while limiting toxicity to normal tissues (Goodwin and Meares Cancer Supplement 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of  
30 antibodies against CSG.

- 16 -

Antibodies which can be used in these *in vivo* methods include polyclonal, monoclonal and omniclonal antibodies and antibodies prepared via molecular biology techniques. Antibody fragments and aptamers and single-stranded  
5 oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

The present invention is further described by the following examples. These examples are provided solely to  
10 illustrate the invention by reference to specific embodiments. These exemplifications, while illustrating certain aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

#### EXAMPLES

15 The examples are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following examples can be carried out as described in standard laboratory manuals, such as  
20 Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

#### Example 1

##### Suppression subtractive hybridization (CLONTECH PCR-SELECT)

25 CLONTECH PCR-SELECT is a PCR based subtractive hybridization method designed to selectively enrich for cDNAs corresponding to mRNAs differentially expressed between two mRNA populations (Diatchenko et al, *Proc. Natl. Acad. Sci. USA*, Vol. 93, pp. 6025-6030, 1996). In this method,  
30 differentially expressed mRNAs are enriched based on a selective amplification. cDNA is prepared from the two mRNA

- 17 -

populations which are to be compared. These include the Tester population which is a cDNA population in which the differentially expressed messages are sought and the Driver population which is a cDNA population in which the

5 differentially expressed transcripts are absent or low. The tester sample is separated in two parts and different PCR adapters are ligated to the 5' ends. Each tester is separately annealed to excess driver in the first annealing and then pooled and again annealed in the second annealing to

10 excess driver. During the first annealing, sequences common to both populations anneal. Additionally the concentration of high and low abundance messages are normalized since annealing is faster for abundant molecules due to the second order kinetics of hybridization. During the second annealing

15 cDNAs unique or overabundant to the tester can anneal together. Such molecules have different adapters at their ends. The addition of additional driver during the second annealing enhances the enrichment of the desired differentially expressed sequences. During subsequent PCR,

20 molecules that have different adapters at each end amplify exponentially. Molecules which have identical adapters, or adapters at only one end, or no adapters (driver sequences) either do not amplify or undergo linear amplification. The end result is enrichment for cDNAs corresponding to

25 differentially expressed messages unique to the tester or up regulated in the tester.

This technique was used to identify transcripts unique to cancer tissues or messages overexpressed in the cancer process. To do this, pairs of samples isolated from a cancer

30 tissue were used as the "tester", and non-cancer tissue as the "driver". The non-cancer "driver" can be from the same

- 18 -

individual and tissue as the tumor (Matched). Alternatively, the "driver" can be from a different individual but the same tissue as the tumor sample (unmatched). In some cases, the "driver" comprises mixtures of cDNAs derived from non-cancer  
5 tissues different from the cancer tissue. This approach allows the identification of transcripts whose expression is specific or up-regulated in the cancer tissue. Such transcripts may or may not be cancer specific in their expression.

10 Subtractive hybridization was carried out using as "tester" a mixture of three RNAs from human adenocarcinomas and as "driver" a mixture of RNAs from five human normal tissues (spleen, pancreas, heart, kidney and small intestine).

The subtracted mixture was cloned and two hundred clones  
15 were sequenced. One of the sequences matched Incyte clone ID 3966820. The electronic Northern for this clone showed the highest number of ESTs came from prostate, compared with other tissues (prostate 107 followed by uterus with 20).

The PCR-select clone detected a transcript of 1.9 kb by  
20 hybridization in Northern blots. Amongst 17 tissues tested prostate showed the highest abundance for this transcript.

#### **Example 2: Relative Quantitation of Gene Expression**

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'- 3'  
25 nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected

- 19 -

by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and  
5 normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were  
10 used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene  
15 were evaluated for every sample in normal and cancer tissues. Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was  
20 done using primers and Taqman probes specific to each target gene. The results were analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

25 Real-Time quantitative PCR was done using the following primers:

pro108 Reverse GCCTTCAGCCGTGGGTAGT (SEQ ID NO:3)

pro108 Forward GACAGCGGCTTCACCTTCTC (SEQ ID NO:4)

The absolute numbers depicted in Table 1 are relative  
30 levels of expression of the CSG referred to herein as pro108 (SEQ ID NO:1) in 11 normal different tissues. All the values

- 20 -

are compared to normal pancreas (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

5 **Table 1: Relative Levels of CSG Prol08 Expression in Pooled Samples**

<b>Tissue</b>	<b>NORMAL</b>
Colon Ascending	4.56
Kidney	0.78
Liver	5.66
Ovary	41.07
Small Intestine	0.78
Spleen	3.29
Stomach	11.39
Testis	2.04
Uterus	15.56
Pancreas	1.00
Prostate	2.32

The relative levels of expression in Table 1 show the highest mRNA expression in ovary (41.07) and uterus (15.56), two female specific tissues. Except for stomach (11.39) that shows high levels of mRNA for prol08, the other tissues including prostate show comparable low levels of expression.

The absolute numbers in Table 1 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 2.

The absolute numbers depicted in Table 2 are relative levels of expression of the CSG prol08 in 70 pairs of matching samples. All the values are compared to normal pancreas (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.



- 21 -

Unmatched samples were used for prostatitis (prostatitis 1 and 2) and Benign Prostate Hyperplasia (BPH 1 to 6).

**Table 2: Relative Levels of CSG Pro108 Expression in Individual Samples**

5	<b>Sample ID</b>	<b>Tissue</b>	<b>Cancer</b>	<b>Benign Diseases</b>	<b>Normal Adjacent Tissue</b>
	Pro12B	Prostate 1	253.40		7.70
	Pro78XB	Prostate 2	1020.46		96.67
	Pro84XB	Prostate 3	2055.11		70.52
	Pro101XB	Prostate 4	872.61		218.58
10	Pro91X	Prostate 5	539.32		195.36
	Pro13XB	Prostate 6	0.60		0.49
	Pro23B	Prostate 7	929.30		747.00
	Pro90XB	Prostate 8	160.50		21.00
	Pro18XB	Prostate 9	45.63		31.49
15	Pro20XB	Prostate 10	312.50		20.00
	Pro34B	Prostate 11	1351.18		142.02
	Pro65XB	Prostate 12	1305.15		8.37
	Pro69XB	Prostate 13	486.50		14.50
	Pro10R	Prostatitis 1		122.45	
20	Pro20R	Prostatitis 2		83.38	
	Pro258BPH	BPH 1		39.33	
	Pro263CBPH	BPH 2		451.98	
	Pro267ABPH	BPH 3		90.78	
	Pro271ABPH	BPH 4		5.21	
25	Pro460ZBPH	BPH 5		15.64	
	ProC032BPH	BPH 6		46.85	
	Bld32XK	Bladder 1	2.86		3.88
	Bld46XK	Bladder 2	15.62		1.45

- 22 -

	Bld66X	Bladder 3	32.67		19.90
	BldTR14	Bladder 4	330.60		235.50
	ClnAS67	Colon 1	71.26		0.51
	ClnRC01	Colon 2	5.08		25.90
5	ClnSG45	Colon 3	19.09		6.61
	ClnSG67	Colon 4	65.12		20.61
	ClnTX01	Colon 5	116.97		6.25
	ClnB34	Colon 6	3.98		2.45
	ClnB56	Colon 7	1.98		1.41
10	ClnC9XR	Colon 8	6.88		2.00
	ClnCXGA	Colon 9	2.25		2.62
	ClnAS89	Colon 10	77.44		2.39
	ClnTX67	Colon 11	167.73		11.51
	End10479	Endometrium 1	7.63		26.67
15	End8911	Endometrium 2	16.19		64.98
	End8963	Endometrium 3	12.14		65.89
	End5XA	Endometrium 4	99.39		23.51
	End65RA	Endometrium 5	6.94		16.06
	Kid109XD	Kidney 1	65.57		41.93
20	Kid10XD	Kidney 2	39.67		9.71
	Kid11XD	Kidney 3	12.68		1.62
	Kid126XD	Kidney 4	43.71		7.59
	Kid12XD	Kidney 5	2.50		70.80
	Kid5XD	Kidney 6	2.11		74.29
25	Kid6XD	Kidney 7	19.36		0.72
	Liv42X	Liver 1	39.00		6.40
	Liv15XA	Liver 2	9.23		4.59
	Liv94XA	Liver 3	7.07		8.09

- 23 -

	LngAC66	Lung 1	47.30		16.20
	LngBR94	Lung 2	106.50		3.40
	LngLC109	Lung 3	9.60		34.10
	LngLC71	Lung 4	70.30		64.00
5	LngSQ56	Lung 5	12.40		53.80
	LngSQ79	Lung 6	108.40		77.20
	Lng60XL	Lung 7	0.55		1.47
	Lng75XC	Lung 8	2.34		3.11
	LngC17X	Lung 9	52.96		31.71
10	LngAC69	Lung 10	654.84		42.67
	LngC20X	Lung 11	2.82		0.22
	Mam47XP	Mammary Gland 1	3.40		1.89
	Mam82XI	Mammary Gland 2	33.29		4.44
	MamB011X	Mammary Gland 3	10.61		1.50
15	MamA06X	Mammary Gland 4	14.62		1.55
	Ovr	Ovary	10.00		8.00
	Pan77X	Pancreas 1	91.27		24.50
	Pan71XL	Pancreas 2	1.55		1.30
	Pan82XP	Pancreas 3	5.49		7.53
20	Pan92X	Pancreas 4	1069.00		688.40
	StoAC99	Stomach 1	50.70		18.60
	StoTA73	Stomach 2	37.70		130.30
	SmI21XA	Small Intestine 1	12.42		5.31
	SmIH89	Small Intestine 2	23.26		2.63
25	Tst39X	Testis	27.95		7.01

- 24 -

Utr85XU	Uterus 1	3.30		4.91
Utr23XU	Uterus 2	44.48		29.04

Table 2 shows the results for the analysis of 148 samples distributed in 14 different tissue types. Tables 1 and 2 represent a combined total of 159 samples in 16 different tissue types.

In the analysis of matching samples, the higher levels of expression were in prostate, showing a high degree of tissue specificity for prostate tissue. Of all the samples different from prostate which were analyzed (57 matching samples), only a few samples (lung 10 and pancreas 4) showed an expression comparable or higher than the median for the mRNA expression in prostate cancer (median: 539.32).

In addition, the level of mRNA expression in cancer samples was compared with the isogenic normal adjacent tissue from the same individual. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 2 shows overexpression of the CSG prol08 in 13 of 13 prostate cancer tissues compared with their respective normal adjacent (prostate samples #1 to #13). Thus, there was overexpression in the cancer tissue for 100% of the prostate matching samples tested.

Altogether, the level of tissue specificity, plus the mRNA overexpression in 100% of the prostate matching samples tested are indicative of the CSG prol08 being a diagnostic marker for prostate cancer.

- 25 -

What is claimed is:

1. A method for diagnosing the presence of prostate cancer in a patient comprising:

(a) measuring levels of CSG in cells, tissues or bodily fluids in a patient; and

(b) comparing the measured levels of CSG with levels of CSG in cells, tissues or bodily fluids from a normal human control, wherein a change in measured levels of CSG in said patient versus normal human control is associated with the presence of prostate cancer.

2. A method of diagnosing metastases of prostate cancer in a patient comprising:

(a) identifying a patient having prostate cancer that is not known to have metastasized;

(b) measuring CSG levels in a sample of cells, tissues, or bodily fluid from said patient; and

(c) comparing the measured CSG levels with levels of CSG in cells, tissue, or bodily fluid of a normal human control, wherein an increase in measured CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

3. A method of staging prostate cancer in a patient having prostate cancer comprising:

(a) identifying a patient having prostate cancer;

(b) measuring CSG levels in a sample of cells, tissue, or bodily fluid from said patient; and

(c) comparing measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in measured CSG levels in said patient

- 26 -

versus the normal human control is associated with a cancer which is progressing and a decrease in the measured CSG levels is associated with a cancer which is regressing or in remission.

5        4.    A method of monitoring prostate cancer in a patient for the onset of metastasis comprising:

      (a) identifying a patient having prostate cancer that is not known to have metastasized;

      (b) periodically measuring levels of CSG in samples of  
10 cells, tissues, or bodily fluid from said patient; and

      (c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CSG levels in the patient versus the  
15 normal human control is associated with a cancer which has metastasized.

      5.    A method of monitoring a change in stage of prostate cancer in a patient comprising:

      (a) identifying a patient having prostate cancer;

20        (b) periodically measuring levels of CSG in cells, tissues, or bodily fluid from said patient; and

      (c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the  
25 periodically measured CSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

- 27 -

6. The method of claim 1, 2, 3, 4 or 5 wherein the CSG comprises SEQ ID NO:1 or SEQ ID NO:2.

7. An antibody which specifically binds CSG.

8. A method of imaging prostate cancer in a patient  
5 comprising administering to the patient an antibody of claim 7.

9. The method of claim 8 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

10. A method of treating prostate cancer in a patient  
10 comprising administering to the patient an antibody of claim 7.

11. The method of claim 10 wherein the antibody is conjugated to a cytotoxic agent.

## SEQUENCE LISTING

<110> Ali, Shijath M.

Sun, Yongming

Salceda, Susana

Recipon, Herve

Cafferkey, Robert

DIADEXUS LLC

<120> A Novel Method of Diagnosing, Monitoring, Staging,  
Imaging and Treating Prostate Cancer

<130> DEX-0048

<140>

<141>

<150> 60/104,741

<151> 1998-10-19

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 1840

<212> DNA

<213> Homo sapiens

<400> 1

```
ctcgaagccgg ggtgcggcag cactgccagg ggaagagggg gatccgaccc ggggaagggtc 60
gctgggcagg gcgagttggg aaagcggcag ccccgccgc ccccgacgc ctttctctc 120
ctttctccca cgtctatct gcctctcgt ggaggccagg ccgtgcagca tcgaagacag 180
gaggaactgg agcctcattg gccggcccg ggcgcggcc tcgggcttaa ataggagctc 240
cgggctctgg ctgggacccg accgctgccg gccgcgctcc cgctgctcct gccgggtgat 300
ggaaaacccc agcccggccg ccgccctggg caaggccctc tgcgctctcc tctggccac 360
tctcggcgcc gccggccagc ctcttggggg agagtccatc tgttcgcca gagccccggc 420
caaatacagc atcaccttca cgggcaagtg gagccagacg gccttcccca agcagtaccc 480
cctgttccgc cccctgcgc agtggctctc gctgctgggg gccgcgcata gctccgacta 540
cagcatgtgg aggaagaacc agtacgtcag taacgggctg cgcgactttg cggagcgagg 600
cgaggcctgg gcgctgatga aggagatcga ggcgggcggg gaggcgctgc agagcgtgca 660
cgagggtgtt tcggcgcccg ccgtccccag cggcaccggg cagacgtcgg cggagctgga 720
ggtgcagcgc aggcactcgc tggctctcgt tgtggtgcgc atcgtgcca gcccgactg 780
gttcgtgggc gtggacagcc tggacctgtg cgacggggac cgttggcggg aacaggcggc 840
gctggacctg taccctacg acgccgggac ggacagcggc ttcaccttct cttccccaa 900
cttcgccacc atcccgagg acacgggtgac cgagataacg tcctcctctc ccagccaccc 960
ggccaactcc ttctactacc cgcggctgaa ggccctgcct cccatcgcca ggggtgacact 1020
ggtgcggctg cgacagagcc ccagggcctt catccctccc gcccagtcct tgcccagcag 1080
```



```

ggacaatgag attgtagaca gcgcctcagt tccagaaacg ccgctggact gcgaggtctc 1140
cctgtgggtcg tcttggggac tgtgctggagg ccactgtggg aggctcggga ccaagagcag 1200
gactcgctac gtccgggtcc agcccgccaa caacgggagc ccctgccccg agctcgaaga 1260
agaggctgag tgcgtccctg ataactgctg ctaagaccag agccccgcag cccctggggc 1320
cccccgagc catgggggtgt cggggggtcc tgtgcaggct catgctgcag gcggccgagg 1380
gcacaggggg tttcgcgctg ctcttgaccg cggtagaggc gcgccgacca tctctgcact 1440
gaagggccct ctggtggccg gcacgggcat tgggaaacag cctcctcctt tcccaacctt 1500
gcttcttagg ggccccctg tcccgtctgc tctcagcctc ctctcctgc aggataaaagt 1560
catccccaag gctccagcta ctctaaatta tgtctcctta taagttattg ctgctccagg 1620
agattgtcct tcatcgcca ggggcctggc tcccacgtgg ttgcagatac ctcagacctg 1680
gtgctctagg ctgtgctgag cccactctcc cgagggcgca tccaagcggg ggccacttga 1740
gaagtgaata aatggggcgg tttcggaagc gtcagtgttt ccatgttatg gatctctctg 1800
cgtttgaata aagactatct ctgttgctca aaaaaaaaaa 1840

```

&lt;210&gt; 2

&lt;211&gt; 331

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Glu Asn Pro Ser Pro Ala Ala Ala Leu Gly Lys Ala Leu Cys Ala
  1              5              10              15

Leu Leu Leu Ala Thr Leu Gly Ala Ala Gly Gln Pro Leu Gly Gly Glu
              20              25              30

Ser Ile Cys Ser Ala Arg Ala Pro Ala Lys Tyr Ser Ile Thr Phe Thr
              35              40              45

Gly Lys Trp Ser Gln Thr Ala Phe Pro Lys Gln Tyr Pro Leu Phe Arg
              50              55              60

Pro Pro Ala Gln Trp Ser Ser Leu Leu Gly Ala Ala His Ser Ser Asp
              65              70              75              80

Tyr Ser Met Trp Arg Lys Asn Gln Tyr Val Ser Asn Gly Leu Arg Asp
              85              90              95

Phe Ala Glu Arg Gly Glu Ala Trp Ala Leu Met Lys Glu Ile Glu Ala
              100             105             110

Ala Gly Glu Ala Leu Gln Ser Val His Glu Val Phe Ser Ala Pro Ala
              115             120             125

Val Pro Ser Gly Thr Gly Gln Thr Ser Ala Glu Leu Glu Val Gln Arg
              130             135             140

Arg His Ser Leu Val Ser Phe Val Val Arg Ile Val Pro Ser Pro Asp

```

145                                      150                                      155                                      160  
 Trp Phe Val Gly Val Asp Ser Leu Asp Leu Cys Asp Gly Asp Arg Trp  
    165                                      170                                      175  
 Arg Glu Gln Ala Ala Leu Asp Leu Tyr Pro Tyr Asp Ala Gly Thr Asp  
    180                                      185                                      190  
 Ser Gly Phe Thr Phe Ser Ser Pro Asn Phe Ala Thr Ile Pro Gln Asp  
    195                                      200                                      205  
 Thr Val Thr Glu Ile Thr Ser Ser Ser Pro Ser His Pro Ala Asn Ser  
    210                                      215                                      220  
 Phe Tyr Tyr Pro Arg Leu Lys Ala Leu Pro Pro Ile Ala Arg Val Thr  
 225                                      230                                      235                                      240  
 Leu Val Arg Leu Arg Gln Ser Pro Arg Ala Phe Ile Pro Pro Ala Pro  
    245                                      250                                      255  
 Val Leu Pro Ser Arg Asp Asn Glu Ile Val Asp Ser Ala Ser Val Pro  
    260                                      265                                      270  
 Glu Thr Pro Leu Asp Cys Glu Val Ser Leu Trp Ser Ser Trp Gly Leu  
    275                                      280                                      285  
 Cys Gly Gly His Cys Gly Arg Leu Gly Thr Lys Ser Arg Thr Arg Tyr  
    290                                      295                                      300  
 Val Arg Val Gln Pro Ala Asn Asn Gly Ser Pro Cys Pro Glu Leu Glu  
 305                                      310                                      315                                      320  
 Glu Glu Ala Glu Cys Val Pro Asp Asn Cys Val  
    325                                      330

&lt;210&gt; 3

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Synthetic

&lt;400&gt; 3

gccttcagcc gtgggtagt

19

&lt;210&gt; 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 4

gacagcggct tcaccttctc

20

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/23764

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/130.1, 141.1, 155.1, 183.1; 435/6, 7.1, 7.23, 7.9, 91.2; 436/501, 504, 505, 547; 514/44; 536/ 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Medline, Biosis, Embase, Cancerlit, Scisearch, WPIDS, USPATFULL

search terms: CSG, cancer specific gene, cancer, diagnosis, staging, prognosis

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	OLSSON et al. CReverse transcriptase-polymerase chain reaction assays for prostate cancer. Urologic Clinics of North America. May 1997. Vol.24, No. 2, pages 367-378.	1-5
Y	CHO-CHUNG. Antisense oligonucleotides for the treatment of cancer. Current Opinion in Therapeutic Patents. 1993. Vol.3, No. 12, pages 1737-1750.	1-5
A, E	BUSSEMAKERS et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Research. 01 December 1999. Vol.59, No 23, pages 5975-5979.	1-5



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* & * document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 FEBRUARY 2000

Date of mailing of the international search report

07 MAR 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

GEETHA P. BANSAL

Telephone No. (703) 305-3955

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/23764

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 39/395, 48/00; C12P/ 19/34; C12Q 1/68; G01N 33/53, 33/574, 33/546, 33/567

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/130.1, 141.1, 155.1, 183.1; 435/6, 7.1, 7.23, 7.9, 91.2; 436/501, 504, 505, 547; 514/44; 536/ 23.5